Trial Profile
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tirasemtiv (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors Cytokinetics
- 25 Mar 2015 Results published in Neurotherapeutics, according to a Cytokinetics media release.
- 24 Nov 2014 New trial record